Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2008

View Archived Issues

LGT/DEN4 tick-borne encephalitis vaccine evaluated in healthy volunteers

No improvement in cognition seen with CERE-120 in Parkinson's disease patients

Romiplostim increases platelet counts in immune thrombocytopenic purpura

XmAb 2513 moves into clinical development

New therapeutics for thrombotic disorders reported in recent AstraZeneca patents

New treatment option for Alzheimer's disease disclosed in recent Merck patent

Renal cancer drug sorafenib inhibits mutant FLT3 in acute myelogenous leukemia

Recent Solvay patent describes new compounds for substance abuse and dependence

Meditrina enters into exclusive global license agreement with AstraZeneca

GSK and Amira enter agreement for FLAP inhibitors for respiratory and cardiovascular disease

FDA accepts for filing and review UCB's BLA for Cimzia for rheumatoid arthritis

Forest pays Glenmark a USD 15 million milestone payment for oglemilast for COPD

BG Medicine and ACS Biomarker enter agreement for biomarker of vascular plaque rupture

4SC and AiCuris enter collaboration to develop antiinfective drug candidates

Idera and Merck KGaA receive Hart-Scott-Rodino clearance for collaboration agreement

Plethora reports preliminary results from PSD-506 incontinence study

Vermillion and Johns Hopkins agree to co-develop molecular diagnostic tests

NHLBI changes intensive blood sugar treatment strategy in ACCORD trial

Study shows efficacy of once-daily atazanavir sulfate/ritonavir in HIV patients

Apex Bioventures and Dynogen announce definitive merger agreement

BioNumerik treats first patient in global Karenitecin phase III trial

Chelsea Therapeutics commences dosing in pivotal phase III droxidopa trial

Hollis-Eden commences phase I/II Triolex trial in ulcerative colitis

Insception Biosciences initiates human clinical trials of new stem cell treatment